NGeneBio Co. Ltd.
NGeneBio Co., Ltd. develops in vitro diagnostics companion diagnostics products and bioinformatics software. It offers BRCAaccuTest and BRCAaccuTest PLUS are reagent kits for breast and ovarian cancer, and hereditary breast and ovarian cancer syndrome; HEMEaccuTest, a clinical NGS kit for hematological malignancies, such as acute myeloid leukemia, acute lymphoid leukemia, myelodysplastic/myelopro… Read more
NGeneBio Co. Ltd. (354200) - Total Assets
Latest total assets as of September 2025: ₩43.94 Billion KRW
Based on the latest financial reports, NGeneBio Co. Ltd. (354200) holds total assets worth ₩43.94 Billion KRW as of September 2025.
Total assets represent everything the company owns and controls, combining both current assets—like cash and cash equivalents, accounts receivable, and inventories—and non-current assets such as property, plant, equipment (PP&E), intangible assets, and long-term investments.
NGeneBio Co. Ltd. - Total Assets Trend (2018–2024)
This chart illustrates how NGeneBio Co. Ltd.’s total assets have evolved over time, based on quarterly financial data. Explore and compare other companies by total assets.
NGeneBio Co. Ltd. - Asset Composition Analysis
Current Asset Composition (December 2024)
NGeneBio Co. Ltd.'s total assets of ₩43.94 Billion consist of 35.4% current assets and 64.6% non-current assets.
| Asset Category | Amount (KRW) | % of Total Assets |
|---|---|---|
| Cash & Equivalents | ₩4.43 Billion | 13.5% |
| Accounts Receivable | ₩719.39 Million | 2.2% |
| Inventory | ₩2.07 Billion | 6.3% |
| Property, Plant & Equipment | ₩12.17 Billion | 36.9% |
| Intangible Assets | ₩2.43 Billion | 7.4% |
| Goodwill | ₩5.39 Billion | 16.4% |
Asset Composition Trend (2018–2024)
This chart illustrates how NGeneBio Co. Ltd.'s asset composition has evolved over time. Understanding changes in asset allocation can provide insights into the company's strategic shifts, capital allocation priorities, and business focus evolution.
Key Asset Composition Facts
- Current vs. Non-Current Assets: NGeneBio Co. Ltd.'s current assets represent 35.4% of total assets in 2024, a decrease from 80.3% in 2018.
- Cash Position: Cash and equivalents constituted 13.5% of total assets in 2024, down from 62.2% in 2018.
- Tangible vs. Intangible: Intangible assets (including goodwill) make up 23.0% of total assets, an increase from 3.0% in 2018.
- Asset Diversification: The largest asset category is property, plant & equipment at 36.9% of total assets.
NGeneBio Co. Ltd. Competitors by Total Assets
Key competitors of NGeneBio Co. Ltd. based on total assets are shown below.
| Company | Country | Total Assets |
|---|---|---|
|
MedPacto Inc
KQ:235980
|
Korea | ₩51.58 Billion |
|
2H0
F:2H0
|
Germany | €15.27 Million |
|
Shenzhen CAU Technology Co Ltd
SHE:000004
|
China | CN¥260.55 Million |
|
Pacific Shuanglin Bio pharmacy Co Ltd
SHE:000403
|
China | CN¥9.58 Billion |
|
Nanhua Bio Medicine Co Ltd
SHE:000504
|
China | CN¥841.96 Million |
|
Jiangsu Sihuan Bioengineering Co Ltd
SHE:000518
|
China | CN¥509.14 Million |
|
Chengzhi Shareholding Co Ltd
SHE:000990
|
China | CN¥27.52 Billion |
|
Hualan Biological EngineeringInc
SHE:002007
|
China | CN¥16.27 Billion |
NGeneBio Co. Ltd. - Asset Efficiency Metrics
Asset efficiency metrics measure how effectively a company uses its assets to generate revenue and profits. These indicators help investors evaluate management's ability to deploy capital efficiently.
Asset Turnover Ratio
Measures how efficiently a company uses its assets to generate sales
Lower asset utilization - NGeneBio Co. Ltd. generates 0.17x its asset value in annual revenue.
Return on Assets (ROA)
Measures how efficiently a company uses its assets to generate profits
Negative ROA - NGeneBio Co. Ltd. is currently not profitable relative to its asset base.
NGeneBio Co. Ltd. - Liquidity and Working Capital Analysis
Liquidity ratios measure a company's ability to pay off its short-term debts as they come due, using the company's current or quick assets. Working capital represents the operational liquidity available.
Key Liquidity Metrics
| Metric | Current | 1 Year Ago | 5 Years Ago |
|---|---|---|---|
| Current Ratio | 0.93 | 0.57 | 6.28 |
| Quick Ratio | 0.86 | 0.48 | 6.09 |
| Cash Ratio | 0.00 | 0.26 | 0.00 |
| Working Capital | ₩-1.99 Billion | ₩ -8.99 Billion | ₩ 35.61 Billion |
NGeneBio Co. Ltd. - Advanced Valuation Insights
This section examines the relationship between NGeneBio Co. Ltd.'s asset base and its market valuation, helping to identify whether the company's assets are efficiently translated into market value.
Key Valuation Metrics
| Current Price-to-Book Ratio | 3.28 |
| Latest Market Cap to Assets Ratio | 0.00 |
| Asset Growth Rate (YoY) | -22.1% |
| Total Assets | ₩32.95 Billion |
| Market Capitalization | $24.40 Million USD |
Valuation Analysis
Below Book Valuation: The market values NGeneBio Co. Ltd.'s assets below their book value (0.00 x), which may indicate investor concerns about asset quality or future growth.
Significant Asset Reduction: NGeneBio Co. Ltd.'s assets decreased by 22.1% over the past year, potentially indicating divestiture, restructuring, or challenging business conditions.
Annual Total Assets for NGeneBio Co. Ltd. (2018–2024)
The table below shows the annual total assets of NGeneBio Co. Ltd. from 2018 to 2024.
| Year | Total Assets | Change |
|---|---|---|
| 2024-12-31 | ₩32.95 Billion | -22.07% |
| 2023-12-31 | ₩42.28 Billion | -24.72% |
| 2022-12-31 | ₩56.16 Billion | +28.03% |
| 2021-12-31 | ₩43.87 Billion | -11.19% |
| 2020-12-31 | ₩49.39 Billion | +267.53% |
| 2019-12-31 | ₩13.44 Billion | +21.04% |
| 2018-12-31 | ₩11.10 Billion | -- |